Topical Spironolactone in the Treatment of Ocular Graft-Versus-Host Disease

    September 2023 in “ Curēus
    Calvin W. Wong, Annie Yang, Chia-Yang Liu, Mitchell A. Watsky, Xiaowen Lu, Hien Thi Thu Le, Richard W. Yee
    New to Spironolactone? There is a guide in the encyclopedia. Read the guide →
    Image
    Studysummary This study reported that topical spironolactone improved lid margin vascularity, corneal fluorescein staining, and disease severity scores in patients with ocular graft-versus-host disease, suggesting a potential therapeutic role by enhancing corneal lipid production with minimal adverse effects.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results